Klow Stack kalkulator

What Is the Klow Stack?

The Klow Stack is BergdorfBio's proprietary anti-aging peptide blend engineered to target the deeper biological mechanisms that drive cellular aging. While many peptide protocols focus on structural regeneration at the tissue level, the Klow Stack operates at a more fundamental level: mitochondrial health, cellular repair signaling, and longevity pathway activation. It is designed for individuals seeking to address aging at the cellular source rather than simply managing its visible consequences.

The stack combines peptide components that work across complementary biological axes — oxidative stress reduction, mitochondrial biogenesis support, and the activation of repair pathways linked to extended cellular lifespan. This makes the Klow Stack particularly relevant for longevity-focused biohackers, athletes seeking accelerated recovery, and individuals in their 40s and beyond who want to maintain biological youth at the cellular level.

Unlike stacks targeting a single organ or tissue system, the Klow Stack's multi-target mechanism reflects the emerging understanding in geroscience that aging is not a single-pathway phenomenon. The hallmarks of aging — mitochondrial dysfunction, cellular senescence, impaired proteostasis, and epigenetic drift — require multi-vector interventions to meaningfully shift trajectory. The Klow Stack is formulated with this scientific framework in mind.

You can find the Klow Stack at BergdorfBio, available as a pre-formulated research combination for scientific purposes.

Biological Targets and Mechanism of Action

Mitochondrial Health and Biogenesis

Mitochondrial dysfunction is one of the most well-characterized hallmarks of aging. As cells age, the efficiency of oxidative phosphorylation declines, reactive oxygen species (ROS) production increases, and the capacity for mitochondrial autophagy (mitophagy) decreases. The Klow Stack includes components that activate the PGC-1alpha pathway — the master regulator of mitochondrial biogenesis — which drives the production of new, functional mitochondria to replace aging ones. This process improves cellular energy production, reduces oxidative burden, and restores the metabolic capacity that declines with age.

Oxidative Stress Reduction

Chronic oxidative stress accelerates nearly every aging phenotype: telomere shortening, protein misfolding, DNA strand breaks, and membrane lipid peroxidation. The Klow Stack targets the Nrf2-Keap1 pathway — the principal cellular defense against oxidative stress — upregulating the expression of antioxidant enzymes including superoxide dismutase (SOD), catalase, glutathione peroxidase, and heme oxygenase-1 (HO-1). This endogenous antioxidant activation is mechanistically superior to exogenous antioxidant supplementation, as it produces a sustained, enzymatic defense rather than a transient molecular scavenging effect.

Tissue Repair and Cellular Renewal

The Klow Stack's tissue repair component supports the body's endogenous repair systems through multiple mechanisms:

• Upregulation of growth hormone receptor expression at the tissue level, enhancing local repair signaling without systemic GH elevation
• Promotion of angiogenesis via VEGF upregulation, ensuring adequate blood supply to tissues undergoing repair and renewal
• Modulation of the nitric oxide (NO) system, supporting vascular function and nutrient delivery to metabolically active tissues
• Activation of stem cell recruitment pathways that bring repair-competent cells to sites of microscopic tissue damage — the type of chronic, low-grade damage that accumulates silently during normal aging

Longevity Signaling Pathways

At the gene-expression level, the Klow Stack engages signaling pathways associated with extended lifespan in multiple model organisms. The AMPK and SIRT1 pathways — both implicated in the caloric restriction response — are modulated by the stack's components. AMPK activation promotes mitophagy, inhibits mTORC1 (which drives cellular senescence when chronically elevated), and enhances cellular stress resistance. SIRT1 activation supports epigenetic maintenance and DNA repair fidelity, two processes that progressively deteriorate with aging.

The Klow Stack also demonstrates activity at the level of telomere-associated proteins, with preliminary research suggesting support for telomerase activity in certain cell types. While telomere extension in humans remains a complex and incompletely understood process, maintaining the integrity of telomere-binding proteins appears relevant to slowing the rate of age-associated cellular senescence.

Dosage Calculation

Accurate dose calculation begins with knowing the concentration of your reconstituted vial. For a standard 10 mg Klow Stack vial reconstituted with 2 ml of bacteriostatic water (BAC water):

10 mg / 2 ml = 5 mg/ml

At this concentration, the most common research dose range of 0.5–2 mg per day translates to:

• 0.5 mg dose: 0.5 ÷ 5 = 0.10 ml (10 units on a U100 insulin syringe)
• 1 mg dose: 1 ÷ 5 = 0.20 ml (20 units)
• 1.5 mg dose: 1.5 ÷ 5 = 0.30 ml (30 units)
• 2 mg dose: 2 ÷ 5 = 0.40 ml (40 units)

Use the Klow Stack calculator above to compute exact injection volumes for any vial size, BAC water volume, and target dose. The formula is always: Injection volume (ml) = Desired dose (mg) / Concentration (mg/ml).

If you prefer a more dilute solution for easier measurement of smaller doses, reconstitute with 4 ml BAC water (yielding 2.5 mg/ml). At this concentration, a 0.5 mg dose equals 0.20 ml — a volume that is easier to measure accurately in a standard insulin syringe.

Dosing Protocol

The Klow Stack is designed for daily administration, reflecting the continuous nature of the biological processes it targets. Mitochondrial health, oxidative stress management, and longevity signaling are not episodic processes — they require consistent, sustained input to shift the cellular equilibrium toward repair and renewal.

Standard Protocol (Subcutaneous)

• Starting dose: 0.5 mg once daily for the first 1–2 weeks to assess tolerance
• Maintenance dose: 1 mg once daily, escalated to 1.5–2 mg as tolerated
• Timing:Morning administration is preferred, as the biological processes targeted by the Klow Stack align with the body's natural daytime metabolic activity. Some users prefer splitting the dose (morning and evening) at higher dose ranges.
• Cycle length: 8–12 weeks on, 4 weeks off; this cycling structure prevents receptor adaptation and maintains signaling responsiveness
• Injection site: Subcutaneous fat of the abdomen (preferred), thigh, or upper arm; rotate sites to minimize local tissue accumulation

Advanced Protocol: Stacking with Glow Stack

Many users combine the Klow Stack with the Glow Stack (GHK-Cu + BPC-157) for a comprehensive anti-aging protocol. In this configuration, the Klow Stack addresses deep cellular and mitochondrial aging while the Glow Stack provides structural regeneration at the tissue and dermal level. The two stacks use complementary but non-overlapping mechanisms, making them ideal for concurrent use without competitive receptor interactions.

Reconstitution

Proper reconstitution is essential for maintaining peptide integrity and ensuring accurate dosing. Follow these steps carefully:

1. Prepare materials: Gather your 10 mg Klow Stack vial, a vial of bacteriostatic water (BAC water), a 1 ml or 3 ml syringe with an 18–21 gauge needle for drawing, a separate fine-gauge insulin syringe for injection, and alcohol swabs.
2. Sterilize surfaces: Wipe the rubber stopper of both the peptide vial and the BAC water vial thoroughly with separate alcohol swabs. Allow to air-dry for at least 30 seconds.
3. Draw BAC water: Using the larger syringe, draw 2 ml of bacteriostatic water.
4. Inject slowly along the wall: Insert the needle into the peptide vial at an angle and allow the BAC water to run slowly down the inner glass wall. Never inject directly onto the lyophilized powder, as the force can break peptide bonds and reduce bioactivity.
5. Dissolve gently: Gently roll the vial between your palms or swirl in a slow circular motion until the powder has completely dissolved. This typically takes 30–90 seconds. Never shake the vial.
6. Inspect the solution: The reconstituted Klow Stack solution should be clear and colorless to faintly straw-colored. Discard any vial showing cloudiness, visible particles, or unusual coloration — these indicate degradation or contamination.
7. Label the vial: Write the reconstitution date and the calculated concentration (5 mg/ml if 2 ml BAC water was used) directly on the vial or on a label.

Storage and Stability

Peptide potency is highly sensitive to storage conditions. Following these guidelines will preserve the Klow Stack's bioactivity throughout its usable window:

• Lyophilized (unreconstituted) powder: Store in the original sealed vial at 2–8°C (refrigerator) for routine storage, or at -20°C (freezer) for long-term preservation exceeding 3 months. Lyophilized peptide is stable for up to 24 months when kept dry and frozen. Protect from light and moisture at all times.
• Reconstituted solution: Store at 2–8°C in the refrigerator, kept upright and away from light. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends usable life to approximately 28 days after reconstitution.
• Freeze-thaw cycles: Avoid freezing reconstituted vials. Repeated freeze-thaw cycles cause peptide aggregation and significant potency loss. If you cannot use a reconstituted vial within 28 days, discard it and reconstitute a fresh vial.
• Temperature exposure: Never leave reconstituted vials at room temperature for extended periods. Temperatures above 25°C accelerate peptide degradation. For brief periods (under 4 hours), room temperature exposure during dose preparation is acceptable.
• Travel: Use a small insulated medical travel case with a cool pack for any journey lasting more than 2–3 hours. Most commercial peptide travel cases maintain 2–8°C for 24–48 hours without requiring ice replacement.

Side Effects and Safety Considerations

The Klow Stack components have been selected in part for their favorable safety profiles in preclinical research. The stack is generally well-tolerated, though individual responses vary and first-time users should begin at the lower end of the dose range.

Common and Transient

• Injection site reactions: Mild redness, local warmth, or minimal swelling at the injection site. These typically resolve within 1–4 hours and are minimized by rotating injection sites and using a fine-gauge needle (29–31 gauge).
• Initial fatigue or mild sedation: Some users report a transient fatigue during the first 3–5 days as mitochondrial reprogramming initiates. This typically resolves as cellular adaptation occurs and energy production normalizes.
• Mild nausea: Occasionally reported with the first few administrations, particularly at doses above 1 mg. Starting at 0.5 mg and gradually titrating upward minimizes this effect.

Less Common

• Transient changes in appetite: Some users notice a brief reduction in appetite during the first week, likely reflecting metabolic recalibration. This effect resolves without intervention in the majority of cases.
• Sleep disturbances: A small minority of users report vivid dreams or altered sleep architecture during the first 1–2 weeks. These effects are temporary and often normalize as the protocol continues.

Contraindications and Cautions

• Not for use during pregnancy or breastfeeding due to insufficient safety data
• Individuals with active malignancy should consult an oncologist before use, as the growth-signaling components of the stack have not been studied in oncological contexts
• Those taking anticoagulants should exercise caution, as some components may theoretically modulate platelet aggregation pathways
• If you are on immunosuppressive medications following organ transplant, consult a physician before beginning any peptide protocol

Combinations and Stacks

The Klow Stack is frequently used as part of a broader anti-aging protocol. The following combinations are commonly explored in the research community:

• Glow Stack (GHK-Cu + BPC-157) — The Klow Stack's most natural companion. While Klow addresses mitochondrial and cellular aging, the Glow Stack provides structural regeneration at the dermal and tissue level. Together they cover two distinct but complementary anti-aging axes. View the Glow Stack at BergdorfBio.
• GHK-Cu — The copper tripeptide provides collagen synthesis support, gene-level repair activation, and potent antioxidant defense that complements the Klow Stack's mitochondrial focus. Can be used standalone or as part of the Glow Stack protocol. View GHK-Cu at BergdorfBio.
• BPC-157 — Body Protection Compound-157 adds tissue repair, angiogenesis, and anti-inflammatory effects that support the systemic repair environment the Klow Stack initiates at the cellular level. View BPC-157 at BergdorfBio.
• SS-31 (Elamipretide)— A mitochondria-targeting peptide that synergizes directly with the Klow Stack's mitochondrial mechanism. SS-31 concentrates at the inner mitochondrial membrane and stabilizes cardiolipin, preserving electron transport chain efficiency. Adding SS-31 to the Klow Stack creates a particularly targeted mitochondrial anti-aging protocol.
• MOTS-c— A mitochondria-derived peptide that activates AMPK and promotes metabolic flexibility. MOTS-c complements the Klow Stack's longevity signaling mechanism and may amplify the AMPK-pathway benefits.

Frequently Asked Questions

How long does the Klow Stack take to produce noticeable effects?

The timeline for Klow Stack effects depends on the biological endpoint being assessed. Subjective improvements in energy levels and cognitive clarity are often reported within the first 2–3 weeks as mitochondrial function improves. Changes in skin quality and physical recovery speed typically become apparent at 4–6 weeks. More fundamental metrics — inflammatory biomarkers, oxidative stress markers, or biological age indicators if testing is undertaken — generally show movement at the 8–12 week mark. The Klow Stack is a long-term investment in cellular health rather than an acutely symptomatic intervention.

Can the Klow Stack and Glow Stack be used simultaneously?

Yes. The two stacks are frequently used together precisely because they address aging through complementary mechanisms with no receptor overlap. The Klow Stack can be administered in the morning and the Glow Stack in the evening, or both can be taken at the same time of day. When starting both simultaneously, consider initiating at half the standard dose for each stack during the first week to assess individual tolerance before reaching full protocol doses.

Is the Klow Stack suitable for both men and women?

Yes. The Klow Stack's mechanisms — mitochondrial biogenesis, oxidative stress defense, and cellular repair activation — are not sex-hormone dependent. Both men and women experience the same age-related mitochondrial decline, making the stack equally relevant across sexes. Women in perimenopause or post-menopause may find the stack particularly beneficial given the accelerated oxidative stress and mitochondrial dysfunction that accompanies estrogen decline.

What syringe size is recommended for the Klow Stack?

A 0.3 ml (30-unit) insulin syringe with a 29–31 gauge, 6–8 mm needle is ideal for most doses in the 0.5–2 mg range when using a 5 mg/ml concentration. For doses approaching 2 mg (0.40 ml at 5 mg/ml), a 0.5 ml syringe provides more comfortable handling. Always use the shortest available needle for subcutaneous administration to ensure the injection remains in the subcutaneous fat layer rather than reaching muscle.

Does the Klow Stack require post-cycle therapy (PCT)?

No. The Klow Stack does not suppress endogenous hormone production and does not interact with the hypothalamic-pituitary axis. It requires no post-cycle therapy. The recommended off-cycle periods (4 weeks after every 8–12 week cycle) serve to prevent receptor adaptation and maintain signaling responsiveness, not to restore hormonal function.

Can the Klow Stack be stacked with performance-enhancing peptides like CJC-1295?

Yes, though the combination should be managed carefully in terms of total peptide load. Growth hormone secretagogues like CJC-1295 operate through the GHRH receptor pathway, which does not overlap with the Klow Stack's primary mechanisms. Some researchers combine these protocols to simultaneously address cellular aging (Klow Stack) and growth hormone pulse optimization (CJC-1295). When combining multiple protocols, always introduce one new compound at a time to establish individual response baselines before adding the next.

How does the Klow Stack differ from the Glow Stack?

The Glow Stack (GHK-Cu + BPC-157) is primarily a tissue-level regeneration stack: it drives collagen synthesis, wound healing, angiogenesis, and dermal repair. Results are often visible externally in skin quality and texture. The Klow Stack operates at a deeper, sub-cellular level — targeting mitochondrial function, cellular energetics, oxidative stress resilience, and longevity signaling. Its effects are more systemic and fundamental, with benefits manifesting across multiple organ systems rather than primarily at the dermal level. The two stacks are designed to be complementary rather than competitive.

Is there a maximum dose for the Klow Stack?

In the research context, doses above 2 mg per day have not demonstrated meaningfully superior outcomes compared to the 1–2 mg range and may increase the likelihood of minor side effects. The current evidence supports the 1–2 mg daily dose range as the optimal research window. Doses above 2 mg are considered experimental and should only be undertaken with appropriate research oversight.

Can the Klow Stack be used during a caloric deficit or fasting protocol?

Yes, and this may actually represent an optimal context for the stack. Caloric restriction and fasting activate many of the same pathways (AMPK, SIRT1, PGC-1alpha) that the Klow Stack engages. Using the Klow Stack during periods of caloric restriction may produce additive activation of these longevity pathways. Adequate hydration is important during fasting protocols, as peptide injection into dehydrated subcutaneous tissue can cause increased local irritation.

Medical Disclaimer: The information on this page is provided for educational and research purposes only. The Klow Stack is not an approved drug or medical treatment. It is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.